GENMEDS

What this means for you

Approved and waiting on proof of use. It will register unless the applicant drops it, and its 23 May 2025 filing date already counts against anyone who files later.

Record

Serial number

99199747

Mark type

Stylized text

Filed

23 May 2025

Published for opposition

21 Apr 2026

Attorney of record

Candice Kwok

Goods and services

• Class 005 — Pharmaceuticals: Pharmaceutical preparations, namely, single-administration gene therapy products for the treatment and long-term management of chronic diseases, namely, metabolic, autoimmune, cardiovascular, infectious, and oncological diseases, and neurological disorders; gene therapy products for medical purposes, namely, pharmaceutical preparations for the treatment of metabolic, autoimmune, cardiovascular, infectious, and oncological diseases, and neurological disorders; therapeutic preparations comprising viral vectors for gene delivery; biopharmaceuticals for modifying genetic expression to treat chronic and inherited conditions, namely, metabolic, autoimmune, cardiovascular, infectious, and oncological diseases, and neurological disorders; injectable gene therapy products for use in treating metabolic, autoimmune, cardiovascular, or neurological disorders; biologics in the nature of pharmaceutical preparations for the treatment of chronic diseases, namely, metabolic, autoimmune, cardiovascular, infectious, and oncological diseases, and neurological disorders, and for the treatment of metabolic, autoimmune, cardiovascular, and neurological disorders; biological preparations for the prevention or treatment of chronic diseases, namely, metabolic, autoimmune, cardiovascular, infectious, and oncological diseases, and neurological disorders; injectable pharmaceutical preparations for treatment of chronic diseases, namely, metabolic, autoimmune, cardiovascular, infectious, and oncological diseases, and neurological disorders; long-duration medicines for treatment of chronic diseases, namely, metabolic, autoimmune, cardiovascular, infectious, and oncological diseases, and neurological disorders

Owner

• General Medicines LLC, Philadelphia, PA, US

Prosecution history

• 24 Mar 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
• 18 Mar 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 18 Mar 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 18 Mar 2026 — TEAS REQUEST FOR RECONSIDERATION RECEIVED
• 16 Jan 2026 — NOTIFICATION OF FINAL REFUSAL EMAILED
• 16 Jan 2026 — FINAL REFUSAL E-MAILED
• 16 Jan 2026 — FINAL REFUSAL WRITTEN
• 26 Dec 2025 — TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
• 26 Dec 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
• 26 Dec 2025 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
• 26 Dec 2025 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
• 26 Dec 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 26 Dec 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 26 Dec 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
• 30 Oct 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED